Biomarker: HER-2/neu

Biomarker subtype: gene

Clinical application: prognosis(unfavorable)

Histology type: endometrial carcinoma

Country: USA

Region: Columbus

Followed up time : 18.6 momth(1-50 momth)

Sample type : tissue

Clinical method: Fluorescence in situ hybridization

Expression pattern : amplification

Description: HER-2/neu gene amplification as detected by fluorescence in situ hybridization in archival material has significant prognostic value.

Approved symbol: ERBB2

Approved name: erb-b2 receptor tyrosine kinase 2

Locus type: gene with protein product

HGNC ID: HGNC:3430

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430

Symbol status: Approved

Previous symbols: NGL

Alias symbols: NEU HER-2 CD340 HER2 c-ERB2 c-ERB-2 MLN-19 p185(erbB2)

Alternative gene group name: MHA", "mHAg", "MiHA", "mHags", " minor H antigen | ErbB family| cluster of differentiation molecules", "cluster of designation molecules|

Subgroup: |Receptor tyrosine kinases| | MicroRNA host genes

OMIM: 164870

Omim link: https://www.omim.org/entry/164870

NCBI name: 2064

NCBI link: https://www.ncbi.nlm.nih.gov/gene/2064

Summary: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

Expression: Ubiquitous expression in kidney (RPKM 34.7), skin (RPKM 30.2) and 24 other tissues

NCBI gene expression https://www.ncbi.nlm.nih.gov/gene/2064#gene-expression

PDB ID: P04626

PDB link: https://www.ebi.ac.uk/pdbe/entry/search/index/?searchParams=%7B%22q_uniprot%22:%5B%7B%22value%22:%22(P04626)%22,%22condition1%22:%22AND%22,%22condition2%22:%22Contains%22%7D%5D,%22resultState%22:%7B%22tabIndex%22:0,%22paginationIndex%22:1,%22perPage%22:%2210%22,%22sortBy%22:%22Sort%20by%22%7D%7D

CC term ID: GO:0038143

CC term name: ERBB3:ERBB2 complex

Source description: REAC | MIRNA| CORUM

Term ID: REAC:R-HSA-9665233| REAC:R-HSA-9665245| REAC:R-HSA-9665244| REAC:R-HSA-9665247| REAC:R-HSA-9665246| REAC:R-HSA-9665251| REAC:R-HSA-9665250| REAC:R-HSA-1251932| REAC:R-HSA-1306955| REAC:R-HSA-9652282| REAC:R-HSA-9665737| REAC:R-HSA-9665230| REAC:R-HSA-9665249| MIRNA:hsa-miR-4790-5p| CORUM:6506| CORUM:7351

Term name: Resistance of ERBB2 KD mutants to trastuzumab | Resistance of ERBB2 KD mutants to tesevatinib| Resistance of ERBB2 KD mutants to sapitinib| Resistance of ERBB2 KD mutants to osimertinib| Resistance of ERBB2 KD mutants to neratinib| Resistance of ERBB2 KD mutants to lapatinib| Resistance of ERBB2 KD mutants to AEE788| PLCG1 events in ERBB2 signaling| GRB7 events in ERBB2 signaling| Drug-mediated inhibition of ERBB2 signaling| Drug resistance in ERBB2 TMD/JMD mutants| Drug resistance in ERBB2 KD mutants| Resistance of ERBB2 KD mutants to afatinib| hsa-miR-4790-5p| ERBB2-SPG1 complex| GDF15-ERBB2 complex